Beijing Beilu Pharmaceutical (300016) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥74.66 Million ≈ $10.93 Million USD) by net assets (CN¥2.37 Billion ≈ $346.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Beijing Beilu Pharmaceutical for the company's overall valuation and market capitalisation.
Beijing Beilu Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing Beilu Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their cash flow conversion efficiency. Explore earnings quality score of Beijing Beilu Pharmaceutical to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
0.059x |
|
Community West Bancshares
NASDAQ:CWBC
|
0.018x |
|
Chengdu Huaqi Houpu Holding Co Ltd
SHE:300471
|
0.017x |
|
Once Upon a Farm, PBC
NYSE:OFRM
|
0.054x |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
0.038x |
|
Stratasys Ltd
NASDAQ:SSYS
|
0.006x |
|
Kvutzat Acro Ltd.
TA:ACRO
|
-0.030x |
|
SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
NASDAQ:HDL
|
0.087x |
Annual Cash Flow Conversion Efficiency for Beijing Beilu Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Beilu Pharmaceutical from 2006 to 2024. View Beijing Beilu Pharmaceutical share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.83 Billion ≈ $267.71 Million |
CN¥163.02 Million ≈ $23.86 Million |
0.089x | +172.27% |
| 2023-12-31 | CN¥1.79 Billion ≈ $261.39 Million |
CN¥58.46 Million ≈ $8.55 Million |
0.033x | -50.75% |
| 2022-12-31 | CN¥1.92 Billion ≈ $281.43 Million |
CN¥127.81 Million ≈ $18.70 Million |
0.066x | +27.42% |
| 2021-12-31 | CN¥2.08 Billion ≈ $305.05 Million |
CN¥108.73 Million ≈ $15.91 Million |
0.052x | -43.93% |
| 2020-12-31 | CN¥1.89 Billion ≈ $276.87 Million |
CN¥176.00 Million ≈ $25.75 Million |
0.093x | -13.95% |
| 2019-12-31 | CN¥1.45 Billion ≈ $212.25 Million |
CN¥156.81 Million ≈ $22.95 Million |
0.108x | -25.83% |
| 2018-12-31 | CN¥1.21 Billion ≈ $176.45 Million |
CN¥175.75 Million ≈ $25.72 Million |
0.146x | +7.54% |
| 2017-12-31 | CN¥1.07 Billion ≈ $156.46 Million |
CN¥144.92 Million ≈ $21.21 Million |
0.136x | +60.46% |
| 2016-12-31 | CN¥901.69 Million ≈ $131.95 Million |
CN¥76.17 Million ≈ $11.15 Million |
0.084x | -2.56% |
| 2015-12-31 | CN¥932.63 Million ≈ $136.47 Million |
CN¥80.85 Million ≈ $11.83 Million |
0.087x | +37.19% |
| 2014-12-31 | CN¥666.33 Million ≈ $97.51 Million |
CN¥42.11 Million ≈ $6.16 Million |
0.063x | -14.55% |
| 2013-12-31 | CN¥559.38 Million ≈ $81.86 Million |
CN¥41.37 Million ≈ $6.05 Million |
0.074x | +69.54% |
| 2012-12-31 | CN¥523.96 Million ≈ $76.67 Million |
CN¥22.86 Million ≈ $3.34 Million |
0.044x | -53.12% |
| 2011-12-31 | CN¥491.47 Million ≈ $71.92 Million |
CN¥45.73 Million ≈ $6.69 Million |
0.093x | +15.98% |
| 2010-12-31 | CN¥467.62 Million ≈ $68.43 Million |
CN¥37.51 Million ≈ $5.49 Million |
0.080x | -39.92% |
| 2009-12-31 | CN¥433.71 Million ≈ $63.46 Million |
CN¥57.91 Million ≈ $8.47 Million |
0.134x | +473.67% |
| 2008-12-31 | CN¥133.23 Million ≈ $19.50 Million |
CN¥-4.76 Million ≈ $-696.67K |
-0.036x | -126.30% |
| 2007-12-31 | CN¥90.33 Million ≈ $13.22 Million |
CN¥12.28 Million ≈ $1.80 Million |
0.136x | -50.49% |
| 2006-12-31 | CN¥71.59 Million ≈ $10.48 Million |
CN¥19.65 Million ≈ $2.88 Million |
0.274x | -- |
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more